clomipramine has been researched along with selegiline in 17 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (35.29) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 7 (41.18) | 29.6817 |
| 2010's | 3 (17.65) | 24.3611 |
| 2020's | 1 (5.88) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Adkison, KK; Humphreys, JE; Mahar Doan, KM; Polli, JW; Serabjit-Singh, CJ; Shampine, LJ; Webster, LO; Wring, SA | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Bleich, S; Gulbins, E; Kornhuber, J; Reichel, M; Terfloth, L; Tripal, P; Wiltfang, J | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Choi, SS; Contrera, JF; Hastings, KL; Kruhlak, NL; Sancilio, LF; Weaver, JL; Willard, JM | 1 |
| Bellman, K; Knegtel, RM; Settimo, L | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Frazer, A; Mendels, J; Savage, DD | 1 |
| Graham, D; Langer, SZ; Tahraoui, L | 1 |
| Cole, JO | 1 |
| Marley, E; Wozniak, KM | 1 |
| Buckholtz, NS; Sparks, DL | 1 |
| Olpe, HR; Schellenberg, A | 1 |
| Bert, B; Fink, H; Harms, S; Langen, B | 1 |
| Fink-Gremmels, J; Schrickx, JA | 1 |
| Lis, M; Sobieszczańska, A; Suszko-Pawłowska, A; Szczypka, M | 1 |
1 review(s) available for clomipramine and selegiline
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
1 trial(s) available for clomipramine and selegiline
| Article | Year |
|---|---|
Where are those new antidepressants we were promised?
Topics: Antidepressive Agents; Bupropion; Clinical Trials as Topic; Clomipramine; Depressive Disorder; Humans; Legislation, Drug; Mianserin; Nomifensine; Propiophenones; Selegiline; United States; United States Food and Drug Administration | 1988 |
15 other study(ies) available for clomipramine and selegiline
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Passive permeability and P-glycoprotein-mediated efflux differentiate central nervous system (CNS) and non-CNS marketed drugs.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blood-Brain Barrier; Cell Line; Cell Membrane Permeability; Central Nervous System Agents; Dogs; Drug Delivery Systems; Permeability; Pharmaceutical Preparations | 2002 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Identification of new functional inhibitors of acid sphingomyelinase using a structure-property-activity relation model.
Topics: Algorithms; Animals; Cell Line; Cell Line, Tumor; Chemical Phenomena; Chemistry, Physical; Enzyme Inhibitors; Humans; Hydrogen-Ion Concentration; Molecular Conformation; Quantitative Structure-Activity Relationship; Rats; Sphingomyelin Phosphodiesterase | 2008 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Development of a phospholipidosis database and predictive quantitative structure-activity relationship (QSAR) models.
Topics: | 2008 |
Comparison of the accuracy of experimental and predicted pKa values of basic and acidic compounds.
Topics: Chemistry, Pharmaceutical; Forecasting; Hydrogen-Ion Concentration; Pharmaceutical Preparations; Random Allocation | 2014 |
Differential effects of monoamine oxidase inhibitors and serotonin reuptake inhibitors on 3H-serotonin receptor binding in rat brain.
Topics: Animals; Brain; Clomipramine; Clorgyline; Fluoxetine; Male; Monoamine Oxidase Inhibitors; Rats; Receptors, Serotonin; Selegiline; Serotonin Antagonists | 1979 |
Effect of chronic treatment with selective monoamine oxidase inhibitors and specific 5-hydroxytryptamine uptake inhibitors on [3H]paroxetine binding to cerebral cortical membranes of the rat.
Topics: Animals; Cerebral Cortex; Citalopram; Clomipramine; Clorgyline; Kinetics; Male; Membranes; Monoamine Oxidase Inhibitors; Paroxetine; Piperidines; Propylamines; Rats; Rats, Inbred Strains; Selegiline; Serotonin | 1987 |
Interactions between relatively selective monoamine oxidase inhibitors and an inhibitor of 5-hydroxytryptamine re-uptake, clomipramine.
Topics: Animals; Arrhythmias, Cardiac; Body Temperature; Cerebral Cortex; Clomipramine; Clorgyline; Drug Interactions; Hyperthermia, Induced; Male; Monoamine Oxidase Inhibitors; Motor Activity; Myoclonus; Rats; Selegiline | 1985 |
Effects of 6-methoxy-1,2,3,4-tetrahydro-beta-carboline (6-MeO-THbetaC) on audiogenic seizures in DBA/2J mice.
Topics: 5-Hydroxytryptophan; Acoustic Stimulation; Animals; Benzofurans; Carbolines; Citalopram; Clomipramine; Clorgyline; Fluoxetine; Harmine; Indoles; Methoxydimethyltryptamines; Mice; Mice, Inbred DBA; N,N-Dimethyltryptamine; Pargyline; Propylamines; Quipazine; Seizures; Selegiline | 1980 |
The sensitivity of cortical neurons to serotonin: effect of chronic treatment with antidepressants, serotonin-uptake inhibitors and monoamine-oxidase-blocking drugs.
Topics: Animals; Benzofurans; Cerebral Cortex; Clomipramine; Clorgyline; Desipramine; Electric Conductivity; gamma-Aminobutyric Acid; Male; Monoamine Oxidase Inhibitors; Neurons; Piperidines; Rats; Selegiline; Serotonin; Serotonin Antagonists | 1981 |
Clomipramine and selegiline: do they influence impulse control?
Topics: Animals; Antidepressive Agents, Tricyclic; Anxiety, Separation; Behavior, Animal; Clomipramine; Male; Monoamine Oxidase Inhibitors; Motor Activity; Rats; Rats, Wistar; Selegiline; Time Factors | 2006 |
Inhibition of P-glycoprotein by psychotherapeutic drugs in a canine cell model.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Line; Clomipramine; Dogs; Fluoxetine; Gene Expression Regulation; Monoamine Oxidase Inhibitors; Selective Serotonin Reuptake Inhibitors; Selegiline | 2014 |
Clomipramine, a tricyclic antidepressant, and selegiline, a monoamine oxidase-B inhibitor, modulate the activity of phagocytic cells after oral administration in mice.
Topics: Administration, Oral; Animals; Antidepressive Agents, Tricyclic; Clomipramine; Female; Granulocytes; Interleukin-1beta; Macrophages, Peritoneal; Male; Mice; Mice, Inbred BALB C; Monoamine Oxidase Inhibitors; Monocytes; Nitric Oxide; Phagocytes; Phagocytosis; Selegiline | 2020 |